Idenix Focusing On HIV Program, Tyzeka Launch Following Clinical Hold On Hep C Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA decision stems mainly from GI concerns that have dogged valopicitabine development, Idenix said.
You may also be interested in...
Does Bristol Nuc’s Possible Cardiac Toxicity Portend A Class Effect?
Bristol-Myers Squibb has halted study of its Phase II nucleoside polymerase inhibitor for hepatitis C due to one trial patient suffering heart failure. It remains unclear if that event is related to the study drug, but do repeated toxicity issues with “nucs” indicate a class effect?
Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
Hepatitis C sector heats up as Novartis gains rights to Debiopharm's leading cyclophilin inhibitor
Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
Hepatitis C sector heats up as Novartis gains rights to Debiopharm's leading cyclophilin inhibitor